04 jan: Fransk præsidentkandidat vil erstatte euroen med ecu-system
04 jan: A&O får godkendelse til køb af egne aktier fra storaktionær
04-01-2017 14:26:34

Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT Study

Relateret indhold
17:05 - 
Fredagens aktier: Mærsk i fuld fart frem - Vestas og Ba..
16:36 - 
Bavarian: Udenlandske kapitalfonde øger væddemålet på k..
19 apr - 
Torsdagens aktier: Mærsk og NKT steg til tops på nyheds..
Relateret debat
20:05 - 
Der er INGEN grund til at købe BAVA før H2 hvor evt pos..
17:45 - 
jeg venter til mandag og ser hvad der sker men jeg tviv..
17:27 - 
De bliver vel ved indtil de har fået skræmt..

  • PROSTVAC® overall survival data anticipated in the second half of 2017

COPENHAGEN, Denmark, January 4, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today provided guidance for the current estimated timing of interim and final overall survival analysis from the PROSPECT study - a placebo controlled Phase 3 study designed to investigate the efficacy of PROSTVAC to prolong the survival of men with metastatic castration-resistant prostate cancer (mCRPC).

The company maintains its previous guidance that full data is expected within this year, albeit in the second half of 2017, with the third interim analysis likely to occur around mid-2017. This estimate is based on a decline in the number of average monthly events currently seen in the PROSPECT study.

"As there has been speculation that the third interim could occur during first quarter of 2017, we believe it is important to update the market on the current estimated timelines for readout of the Phase 3 study" said Paul Chaplin, President and CEO of Bavarian Nordic.

While the company remains blinded to all patient specific data, the latest estimates have been provided by the independent Data Monitoring Committee (DMC) following a routine analysis of the current survival data.

"While we will have to await the final read out of the PROSPECT study to establish the efficacy of PROSTVAC, we are encouraged that the current monthly event rate has declined. This is great news for the patients. Not only is this consistent with an improvement in the standard of care for patients with mCRPC, which has been observed in recent years, but could also be indicative of a therapeutic effect of PROSTVAC as well" said Paul Chaplin.

About the PROSPECT study

PROSPECT is a global, randomized, double-blind, placebo-controlled phase 3 study being conducted under a Special Protocol Assessment (SPA) from the FDA. The objective of the study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival. The study has been fully enrolled with 1,297 asymptomatic or minimally symptomatic mCRPC patients as of January 2015. Patients were enrolled at more than 200 sites in 15 countries. Both the first and second interim analyses confirmed that the study would continue as planned. Final study data requires 534 events in both comparisons of treatment arms versus placebo, and the third interim analysis will occur at 427 events.

About PROSTVAC

PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec, or "rilimogene") is a prostate specific antigen (PSA)-targeted immunotherapy candidate designed to enhance or stimulate the body's immune response, specifically T cells that will home to and kill prostate cancer cells, altering the course of the disease and improving overall survival (OS) of patients with prostate cancer. A robust data package has been established that includes 18 ongoing or completed clinical studies, comprising more than 2,000 patients of which more than 1,100 patients have been actively treated with PROSTVAC, which has been generally well-tolerated. A randomized, placebo-controlled Phase 2 trial demonstrated the potential of PROSTVAC to extend the median overall survival by 8.5 months in patients with advanced prostate cancer. These results led to the initiation of the PROSPECT pivotal Phase 3 study.

PROSTVAC is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 02 / 2017

2017-02-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2017-02-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
14 apr
BAVA
Som det nok er mange bekendt, er kursen på Bavarians aktie faldet meget betydeligt, ca. 30%, over de..
31
19 apr
BAVA
      Vedr. shortsqeeze mm. og den ekstreme kursmanipulation der dagligt foregår på Nasdaq Kbhvn. T..
19
18 apr
BAVA
Jeg tror nok der er nogen, der sidder lidt længere ude på stolen i dag. Det skulle ikke undre mig om..
11
17 apr
BAVA
Aamund har alle dage været rigtig god til at tale.........for sin syge moster. Jeg har ingen fidus t..
11
17 apr
BAVA
Nu har AA aldrig været kendt for, at være ramt af biotek aktie-pessimisme, så med en skovl salt til,..
9
09:38
BAVA
Det er ikke hans skyld. Det er disse shortere der bare skal have dens mindste anledning til at sælge..
5
18 apr
BAVA
@Henry1, jeg må indrømme, at det af og til er bare en anelse trættende at læse dine Bavarian indlæg...
5
16 apr
BAVA
Sidder og læser årsrapporten på BAVAs hjemmeside før i morgen. Og i denne er der på ingen måde lagt ..
5
18 apr
BAVA
GSA Capital Partners LLP holds a short position at 0.54 % in shares issued by Bavarian Nordic A/S Gi..
4
17 apr
BAVA
Ja kan ikke rigtig lide AA kommentar omkring det kortsigtet, det langsigtet er jeg 100% enig i.   Ko..
4

Bavarian: Udenlandske kapitalfonde øger væddemålet på kursfald

20-04-2018 16:36:15
En række kapitalfonde har onsdag og torsdag øget sine shortpositioner i biotekselskabet Bavarian Nordic. Det viser en række indberetninger til Finanstilsynet. Torsdag har Capital Partners øget sin shortposition til 0,62 pct. af aktierne fra 0,54 pct. Ligeledes har AHL Partners øget sin shortposition til 1,31 pct. af Bavarian-aktierne. Tidligere havde kapitalfonden shortet 1,20 pct.Arrow Street øge..

Vestas-konkurrent sælger flere vindmøller - men prispresset fortsætter

20-04-2018 12:49:56
Den amerikanske Vestas-konkurrent General Electric (GE) har solgt flere vindmøller i første kvartal, men selskabet melder om fortsat prispres i branchen. GE havde i de første tre måneder af 2018 en ordreindgang på 936 vindmøller mod 589 i samme periode sidste år. Selskabet oplyser ikke størrelsen på de solgte møller, men skriver i en kommentar, at det har haft en stærk vækst i USA målt på megawatt..

Brøndby-aktien banker til vejrs efter sejr over guldrival

20-04-2018 09:20:41
Aktien i Brøndby IF bliver sendt til vejrs med en stigning på 13,6 pct. til 1,25 kr. fredag morgen, efter at fodboldklubben torsdag aften vandt 3-2 på udebane over FC Midtjylland i Alka Superligaen.Med sejren fastholder Brøndby IF sin førsteplads i Alka Superligaen og har nu tre point ned til netop FC Midtjylland på andenpladsen. Der mangler at blive spillet seks runder, før sæsonen er slut i Alka..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Tyder på flad åbning med Vestas i fokus
2
Vestas/SHB: Sænker anbefaling og kursmål - NY
3
Vestas/SHB: Sænker anbefaling og kursmål
4
Brøndby-aktien banker til vejrs efter sejr over guldrival
5
Vestas-konkurrent sælger flere vindmøller - men prispresset fortsætter

Relaterede aktiekurser

Bavarian Nordic A/S 169,70 -3,2% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. april 2018 20:09:53
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20180417.1 - EUROWEB6 - 2018-04-20 20:09:53 - 2018-04-20 20:09:53 - 1 - Website: OKAY